Personalized mRNA Vaccine Keeps 87 Percent of Pancreatic Cancer Responders Alive at Six Years, AACR Data Show
Six-year follow-up from a 16-patient Phase 1 trial of autogene cevumeran shows unprecedented survival rates in one of oncology's deadliest cancers, now entering a global Phase 2 trial.
6 min read4 sources